Warrick score in rheumatoid-arthritis interstitial lung disease: a promising tool for assessing the extent and progression of lung involvement

Table 2 Baseline demographic, clinical, and laboratory features at the time of ILD diagnosis

		Mean ± SD or Median [Q1-Q3]
Age at RA diagnosis		54.1 ± 10.7
Age at ILD diagnosis		60.61 ± 8.68
Gender (female) (n, %)		45/77
Disease duration (years)		8.41 ± 7.07
DAS28-ESR		3.32 ± 1.24
Swollen joint (n, %)		-
Tender joint (n, %)		-
Cough (n, %)		22/67
Dyspnea (n, %)		17/67
Velcro crackles (n, %)		24/66
Smoking (n, %)
	Never	39/74
	Active	24/74
	Quit	11/74
Smoking (pack-year)		22.55 ± 15.51
ESR		32.13 ± 25.57
CRP		0.69 ± 0.75
FVC (%)		87 [74.5–99.5]
DLCO (%)		62 [45.75–84.5]
Anti-RF (positive) (n, %)		63/76
Anti-CCP (positive) (n, %)		56/75
Interval between consecutive HRCT		5.36 ± 3.5

ILD, interstitial lung disease; DAS28-ESR, Disease Activity Score-28; ESR, erythrocyte sedimentation rate; CRP, C-Reactive Protein; FVC, forced vital capacity; DLCO, diffusing capacity of carbon monoxide; anti-RF, anti- Rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide

ISSN: 2523-3106